Alvotech (ALVO) Revenue & Revenue Breakdown
Alvotech Revenue Highlights
Latest Revenue (Y)
$91.43M
Latest Revenue (Q)
$12.43M
Main Segment (Y)
Humira
Main Geography (Y)
Europe
Alvotech Revenue by Period
Alvotech Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $91.43M | 10.12% |
| 2022-12-31 | $83.03M | 125.79% |
| 2021-12-31 | $36.77M | -44.80% |
| 2020-12-31 | $66.62M | 108.71% |
| 2019-12-31 | $31.92M | - |
Alvotech generated $91.43M in revenue during NA 2023, up 10.12% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Alvotech Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $12.43M | -76.72% |
| 2023-12-31 | $53.39M | 200.13% |
| 2023-08-31 | $17.79M | 305.12% |
| 2023-06-30 | $4.39M | -72.32% |
| 2023-03-31 | $15.86M | -33.51% |
| 2022-12-31 | $23.86M | 25.22% |
| 2022-09-30 | $19.05M | -51.97% |
| 2022-06-30 | $39.67M | 8675.66% |
| 2022-03-31 | $452.00K | -98.70% |
| 2021-12-31 | $34.76M | 6385.82% |
| 2021-09-30 | $536.00K | -94.17% |
| 2021-06-30 | $9.19M | - |
| 2021-03-31 | $9.19M | -44.80% |
| 2020-12-31 | $16.65M | - |
| 2020-09-30 | $16.65M | - |
| 2020-06-30 | $16.65M | - |
| 2020-03-31 | $16.65M | 108.71% |
| 2019-12-31 | $7.98M | - |
| 2019-09-30 | $7.98M | - |
| 2019-06-30 | $7.98M | - |
| 2019-03-31 | $7.98M | - |
Alvotech generated $12.43M in revenue during Q1 2024, up -76.72% compared to the previous quarter, and up 52.10% compared to the same period a year ago.
Alvotech Revenue Breakdown
Alvotech Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 |
|---|---|
| Humira | $12.20B |
Alvotech's latest annual revenue breakdown by segment (product or service), as of Dec 23: Humira (100.00%).
Alvotech Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 |
|---|---|---|
| North America | $18.31M | $30.78M |
| Asia And Other | $9.62M | - |
| Europe | $63.51M | $39.43M |
| Other Geographical Area | - | $6.02M |
| Asia | - | $6.80M |
Alvotech's latest annual revenue breakdown by geography, as of Dec 23: Europe (69.46%), North America (20.02%), and Asia And Other (10.52%).
Alvotech Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| CTLT | Catalent | $4.38B | $1.07B |
| ALKS | Alkermes | $1.66B | $399.13M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| ASRT | Assertio | $152.07M | $31.13M |
| LFCR | Lifecore Biomedical | $128.26M | $35.70M |
| ALVO | Alvotech | $91.43M | $12.43M |
| CYTH | Cyclo Therapeutics | $1.08M | $123.10K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
ALVO Revenue FAQ
What is Alvotech’s yearly revenue?
Alvotech's yearly revenue for 2023 was $91.43M, representing an increase of 10.12% compared to 2022. The company's yearly revenue for 2022 was $83.03M, representing an increase of 125.79% compared to 2021. ALVO's yearly revenue for 2021 was $36.77M, representing a decrease of -44.80% compared to 2020.
What is Alvotech’s quarterly revenue?
Alvotech's quarterly revenue for Q1 2024 was $12.43M, a -76.72% decrease from the previous quarter (Q4 2023), and a -21.65% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $53.39M, a 200.13% increase from the previous quarter (Q3 2023), and a 123.78% increase year-over-year (Q4 2022). ALVO's quarterly revenue for Q3 2023 was $17.79M, a 305.12% increase from the previous quarter (Q2 2023), and a -6.63% decrease year-over-year (Q3 2022).
What is Alvotech’s revenue growth rate?
Alvotech's revenue growth rate for the last 3 years (2021-2023) was 148.65%, and for the last 5 years (2019-2023) was 186.47%.
What are Alvotech’s revenue streams?
Alvotech's revenue streams in c 23 are Humira
What is Alvotech’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Alvotech was Humira. This segment made a revenue of $12.2B, representing 100.00% of the company's total revenue.